Company news

Precision BioSciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

April 1, 2025

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

March 26, 2025

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

March 21, 2025

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

March 20, 2025

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

March 19, 2025

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

March 17, 2025

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

February 24, 2025

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

February 19, 2025

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

January 28, 2025

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

January 8, 2025

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

December 17, 2024

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

November 14, 2024

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

November 3, 2024

Precision BioSciences to Report Third Quarter Results on November 4, 2024

October 28, 2024

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

October 27, 2024

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

October 23, 2024

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

September 29, 2024

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

September 11, 2024

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

September 2, 2024

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis

August 8, 2024

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

July 31, 2024

Precision BioSciences Announces its Addition to the Russell Microcap® Index

June 30, 2024

Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025

June 26, 2024

Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness

June 19, 2024

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 12, 2024

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

May 7, 2024

Precision BioSciences to Report First Quarter Results on May 13, 2024

May 6, 2024

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

May 6, 2024

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024

April 30, 2024

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

April 15, 2024

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

March 26, 2024

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024

March 19, 2024

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

March 5, 2024

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants

February 29, 2024

Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants

February 28, 2024

Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences

February 19, 2024

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness

February 13, 2024

Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations

February 12, 2024

Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases

February 11, 2024

Precision BioSciences to Effect a Reverse Stock Split

February 8, 2024

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

January 8, 2024

Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE

December 12, 2023

Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

December 3, 2023

Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

November 27, 2023

Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

November 8, 2023

Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update

November 6, 2023

Precision BioSciences to Report Third Quarter Results on November 7, 2023

October 31, 2023

Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

October 25, 2023

Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases

September 26, 2023

Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments

September 11, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 52 decks. Every deck is listed under its year.